How to buy Autolus Therapeutics stock | $6.63

Autolus Therapeutics plc is a biotechnology business based in the US. Autolus Therapeutics shares (AUTL) are listed on the NASDAQ and all prices are listed in US Dollars. Autolus Therapeutics employs 376 staff and has a trailing 12-month revenue of around 0.00.

Autolus Therapeutics stock price (NASDAQ: AUTL)

Use our graph to track the performance of AUTL stocks over time.

Autolus Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-24.

Latest market close	$6.63
52-week range	$4.60 - $16.78
50-day moving average	$6.78
200-day moving average	$6.73
Wall St. target price	$15.94
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.40

Buy Autolus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Autolus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Autolus Therapeutics plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Autolus Therapeutics price performance over time

Historical closes compared with the close of $6.63 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	-0.15%
3 months (2021-04-30)	13.92%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Autolus Therapeutics financials

Revenue TTM	$1.1 million
Gross profit TTM	$-133,173,000
Return on assets TTM	-22.28%
Return on equity TTM	-29.62%
Profit margin	0%
Book value	$5.91
Market capitalisation	$389.6 million

TTM: trailing 12 months

Shorting Autolus Therapeutics shares

There are currently 2.0 million Autolus Therapeutics shares held short by investors – that's known as Autolus Therapeutics's "short interest". This figure is 11.7% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting Autolus Therapeutics shares can be evaluated.

Autolus Therapeutics's "short interest ratio" (SIR)

Autolus Therapeutics's "short interest ratio" (SIR) is the quantity of Autolus Therapeutics shares currently shorted divided by the average quantity of Autolus Therapeutics shares traded daily (recently around 2.2 million). Autolus Therapeutics's SIR currently stands at 0.9. In other words for every 100,000 Autolus Therapeutics shares traded daily on the market, roughly 900 shares are currently held short.

However Autolus Therapeutics's short interest can also be evaluated against the total number of Autolus Therapeutics shares, or, against the total number of tradable Autolus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Autolus Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Autolus Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0591% of the tradable shares (for every 100,000 tradable Autolus Therapeutics shares, roughly 59 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Autolus Therapeutics.

Find out more about how you can short Autolus Therapeutics stock.

Autolus Therapeutics share dividends

We're not expecting Autolus Therapeutics to pay a dividend over the next 12 months.

Autolus Therapeutics share price volatility

Over the last 12 months, Autolus Therapeutics's shares have ranged in value from as little as $4.6 up to $16.78. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Autolus Therapeutics's is 1.6871. This would suggest that Autolus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Autolus Therapeutics overview

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. .

Frequently asked questions

What percentage of Autolus Therapeutics is owned by insiders or institutions?
Currently 26.09% of Autolus Therapeutics shares are held by insiders and 36.097% by institutions. How many people work for Autolus Therapeutics?
Latest data suggests 376 work at Autolus Therapeutics. When does the fiscal year end for Autolus Therapeutics?
Autolus Therapeutics's fiscal year ends in September. Where is Autolus Therapeutics based?
Autolus Therapeutics's address is: Forest House, London, United Kingdom, W12 7RZ What is Autolus Therapeutics's ISIN number?
Autolus Therapeutics's international securities identification number is: US05280R1005 What is Autolus Therapeutics's CUSIP number?
Autolus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 05280R100